ArriVent BioPharma market cap AVBP
Share price times shares outstanding: what the whole company sells for, since 2024.
- Today, Nov 2, 2026
- $658.3M
- Highest close in our data
- $1.6B
- Jul 2026
ArriVent BioPharma is worth $658.3M at the close on Nov 2, 2026, at $13.35 a share.
That is down 10% over the last year.
Its highest close in our data was $1.6B in Jul 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $658.3M | $658.3M | $1.6B | −27% |
| 2025 | $907M | $558.5M | $1B | −1% |
| 2024 | $918.6M | $592.8M | $1.1B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest ArriVent BioPharma's size, closest first, today.
| Company | Market cap |
|---|---|
| AVBPArriVent BioPharma | $658.3M |
| ZVRAZevra Therapeutics | $599.8M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| COLLCollegium Pharmaceutical | $770.9M |
| ABUSArbutus Biopharma | $791.4M |
| PBYIPuma Biotechnology | $525.5M |
| ARVNArvinas | $491.7M |
| CRMDCorMedix | $420.1M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.3B |
| ANABAnaptysbio | $1.4B |
| Peer median | $685.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on ArriVent BioPharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.